Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Alkermes

Founders Floyd Bloom John Clarke Paul Schimmel

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 11
Average round size
info
The average size of a deal this fund participated in
$33M
Portfolio companies 10
Rounds per year 0.92
Lead investments 9
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.09
Exits 2
Key employees 1

Areas of investment

  • Non Profit
  • Therapeutics
  • Life Science
  • Biotechnology
  • Biopharma
Summary

Alkermes appeared to be the Corporate Investor, which was created in 2011. The main department of described Corporate Investor is located in the Waltham. The company was established in North America in United States.

Among the various public portfolio startups of the fund, we may underline Civitas Therapeutics For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Therapeutics, Biotechnology.

The top activity for fund was in 2014. The increased amount of exits for fund were in 2014. The fund is constantly included in less than 2 investment rounds annually. The usual things for fund are deals in the range of 10 - 50 millions dollars.

The typical case for the fund is to invest in rounds with 9 participants. Despite the Alkermes, startups are often financed by Longitude Capital, Canaan Partners, RA Capital Management. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, Longitude Capital, Fountain Healthcare Partners. In the next rounds fund is usually obtained by Wellington Management, Sofinnova Investments, Rock Springs Capital.

The current fund was established by Floyd Bloom, John Clarke, Paul Schimmel.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Alkermes:
Typical Co-investors
Alkermes is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Alkermes:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Angel Forum British Columbia, Canada, Vancouver
Apex Capital New York, New York, United States
Capital One Illinois, United States, Virginia
Dynamic Capital -
Finpiemonte -
Ipsen Boulogne-Billancourt, France, Ile-de-France
Kimura Jitsugyo Japan, Kyoto, Kyoto Prefecture
Korea Asset Investment Securities -
MIG AG Bayern, Germany, München
Orza Investments Pais Vasco, San Sebastian, Spain
Prudence Investment Management China, Hong Kong, Hong Kong Island
Qingchuang Keji Fuhuaqi Beijing, China, Haidian
Roynat Equity Partners Alberta, Calgary, Canada
SaaStr Fund California, Palo Alto, United States
Sprout Group New York, New York, United States
Technology Associates Reston, United States, Virginia
TRICEPIED Ashiya, Hyogo Prefecture, Japan
Yes Bank India, Maharashtra, Mumbai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Civitas Therapeutics

Biopharma
Biotechnology
Life Science
Therapeutics
$55M25 Aug 2014 Chelsea, Massachusetts, United States

Civitas Therapeutics

Biopharma
Biotechnology
Life Science
Therapeutics
$38M11 Sep 2013 Chelsea, Massachusetts, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Alkermes?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 11
Average round size 33M
Rounds per year 0.92
Peak activity year 2023
Lead investments 9
Follow on index 0.09
Exits 2
Group Appearance index 0.18

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Civitas Therapeutics

Biopharma
Biotechnology
Life Science
Therapeutics
$55M25 Aug 2014 Chelsea, Massachusetts, United States

Civitas Therapeutics

Biopharma
Biotechnology
Life Science
Therapeutics
$38M11 Sep 2013 Chelsea, Massachusetts, United States
Crunchbase icon

Content report

The following text will be sent to our editors: